Company Filing History:

13 out of 4,770

Merck + Co., Inc.

patents

1 out of 2,405

Merck Sharp + Dohme Corp.

patents

Years Active: 1994-2011

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 7927870 - DNA vaccine formulations (2011-04-19),

2. 7456009 - Adenovirus formulations (2008-11-25),

3. 7351415 - Adenovirus formulations (2008-04-01),

4. 6616931 - Rotavirus vaccine formulations (2003-09-09),

5. 6403098 - Rotavirus vaccine formulations (2002-06-11),

6. 6387695 - DNA pharmaceutical formulations comprising citrate or triethanolamine and combinations thereof (2002-05-14),

7. 6358744 - Stabilized human papillomavirus formulations (2002-03-19),

8. 6290967 - Stabilizers for lyophilized vaccines (2001-09-18),

9. 6251678 - Human papillomavirus vaccine formulations (2001-06-26),

10. 6245568 - Human papilloma virus vaccine with disassembled and reassembled virus-like particles (2001-06-12),

11. 6210683 - Stabilizers containing recombinant human serum albumin for live virus vaccines (2001-04-03),

12. 6051238 - Stabilizers for lyophilized mumps vaccines (2000-04-18),

13. 5932223 - Rotavirus vaccine formulations (1999-08-03),

14. 5348941 - Stabilizers for fibroblast growth factors (1994-09-20),

Title: The Innovative Contributions of David B Volkin

Introduction

David B Volkin is a prominent inventor based in Doylestown, PA (US), known for his significant contributions to the field of pharmaceutical formulations. With a total of 14 patents to his name, Volkin has made remarkable advancements in the development of DNA vaccines and viral formulations.

Latest Patents

One of Volkin's latest patents focuses on DNA vaccine formulations. This invention relates to novel methods and formulations of nucleic acid pharmaceutical products, specifically targeting nucleic acid vaccine products and gene therapy products. The formulations disclosed stabilize the conformation of DNA pharmaceutical products, enhancing their efficacy. Another notable patent involves adenovirus formulations, which pertain to viral formulations and related pharmaceutical products for gene therapy and vaccine applications. These liquid adenovirus formulations demonstrate improved stability when stored in the 2-8°C range and are compatible with parenteral administration. The formulations include a buffer, sugar, salt, divalent cation, non-ionic detergent, and a free radical scavenger or chelating agent to inhibit free radical oxidation.

Career Highlights

Throughout his career, Volkin has worked with leading companies in the pharmaceutical industry, including Merck & Co., Inc. and Merck Sharp & Dohme Corp. His work has significantly impacted the development of innovative therapeutic solutions.

Collaborations

Volkin has collaborated with esteemed colleagues such as Carl J Burke and Robert K Evans, contributing to the advancement of research and development in his field.

Conclusion

David B Volkin's innovative work in DNA vaccine and viral formulations has established him as a key figure in pharmaceutical research. His contributions continue to influence the development of effective therapeutic products.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Inventor’s Patent Attorneys refers to legal professionals with specialized expertise in representing inventors throughout the patent process. These attorneys assist inventors in navigating the complexities of patent law, including filing patent applications, conducting patent searches, and protecting intellectual property rights. They play a crucial role in helping inventors secure patents for their innovative creations.